Although blood test reduces deaths by two for every 1,000 men screened, many could face unnecessary treatment ...
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...
It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...
CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results